ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 17 of 33
Up
JMBS 2021, 6(4): 119–125
https://doi.org/10.26693/jmbs06.04.119
Clinical Medicine

Markers of Immune Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Combination with Chronic Obstructive Pulmonary Disease

Khramtsova I. O., Derbak M. A.
Abstract

The purpose of the study was to determine markers of immune inflammation in patients with nonalcoholic fatty liver disease combined with chronic obstructive pulmonary disease. Materials and methods. The observation revealed 82 patients who were treated in the pulmonology and gastroenterology department of the Andriy Novak Transcarpathian Regional Clinical Hospital during 2018-2020 with a diagnosis of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease II group B and C. Among the examined there were 61.0% (50) men and 40.0% (32) women. The average age was 57.8±1.5 years old. Results and discussion. As a result of the conducted research it is established that increased levels of chronic immune inflammation markers were observed in all examined with significant increase in patients with a comorbid condition. The highest concentrations of C-reactive protein were found in patients with nonalcoholic fatty liver disease combined with chronic obstructive pulmonary disease with frequent exacerbations and hospitalization, and exceeded the normal values by 8.3 times. The levels of tumor necrosis factor-α and neopterin in patients with frequent exacerbations of chronic obstructive pulmonary disease and hospitalization were by 2.7 times and 1.9 times higher than in patients with a small number of exacerbations and by 3.2 and 3.9 times higher than in patients with nonalcoholic fatty liver disease without chronic obstructive pulmonary disease. The indexes of interleukin-6, transforming growth factor-β, the number of IgG antibodies to neutrophil elastase and the level of tissue inhibitor of matrix proteinases-1 remain consistently high in all patients with combined pathology of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease regardless of the frequency of exacerbations, thus supporting inflammation even in remission. Elastase antibody levels correlate directly with the levels of the tissue metalloproteinase-1 inhibitor and increase with the degree of severety of fibrosis, which may indicate a high level of serum neutrophil elastase activity in patients with nonalcoholic fatty liver disease in combination with chronic obstructive pulmonary disease and its participation in fibrosis. Conclusion. Patients with nonalcoholic fatty liver disease in combination with chronic obstructive pulmonary disease showed an increased level of chronic systemic inflammation of low intensity based on the analysis of C-reactive protein, tumor necrosis factor-α, neopterin and interleukin-6 compared with nonalcoholic fatty liver disease without chronic obstructive pulmonary disease even in remission, which indicates an aggravating course of the disease in combination of two pathologies. Stably high concentration of IgG antibodies to neutrophil elastase may indirectly indicate the maintenance of the activity of this enzyme in the serum of patients with nonalcoholic fatty liver disease in chronic obstructive pulmonary disease and confirms its participation in liver fibrogenesis

Keywords: markers of immune inflammation, nonalcoholic fatty liver disease, fibrosis, chronic obstructive pulmonary disease, exacerbation

Full text: PDF (Ukr) 519K

References
  1. Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open. 2020; 10(8): e036663. https://doi.org/10.1136/bmjopen-2019-036663
  2. Younossi ZM. Non-alcoholic fatty liver disease--A global public health perspective. J Hepatol. 2019; 70(3): 531-44. https://www.ncbi.nlm.nih.gov/pubmed/30414863. https://doi.org/10.1016/j.jhep.2018.10.033
  3. Bedossa P, Tordjman J, Aron-Wisnewsky J, Poitou C, Oppert J-M, Torcivia A, et al. Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. Gut. 2017; 66(9): 1688-96. https://www.ncbi.nlm.nih.gov/pubmed/27884920 . https://doi.org/10.1136/gutjnl-2016-312238
  4. Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular mechanisms: connections between nonalcoholic fatty liver disease, steatohepatitis and hepatocellular carcinoma. Int J Mol Sci. 2020; 21(4): 1525. https://www.ncbi.nlm.nih.gov/pubmed/32102237. https://www.ncbi.nlm.nih.gov/pmc/articles/7073210. https://doi.org/10.3390/ijms21041525
  5. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016; 9(2): 65-90. https://www.ncbi.nlm.nih.gov/pubmed/27055256. https://www.ncbi.nlm.nih.gov/pmc/articles/5644799. https://doi.org/10.1159/000443344
  6. Viglino D, Jullian-Desayes I, Minoves M, Aron-Wisnewsky J, Leroy V, Zarski J-P, et al. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 2017; 49(6): 1601923. https://www.ncbi.nlm.nih.gov/pubmed/28596431. https://doi.org/10.1183/13993003.01923-2016
  7. Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther. 2019; 198: 160-88. https://www.ncbi.nlm.nih.gov/pubmed/30822464. https://www.ncbi.nlm.nih.gov/pmc/articles/7112632. https://doi.org/10.1016/j.pharmthera.2019.02.013
  8. Yazici O, Gulen ST, Yenisey C, Eryilmaz U, Abas BI, Polatli M, et al. Comparison of inflammation biomarkers among chronic obstructive pulmonary disease groups: a cross sectional study. Niger J Clin Pract. 2020; 23(6): 817-824. https://www.ncbi.nlm.nih.gov/pubmed/32525117. https://doi.org/10.4103/njcp.njcp_222_19
  9. Huang YL, Min J, Li GH, Zheng YQ, Wu LH, Wang SJ, et al. The clinical study of comorbidities and systemic inflammation in COPD. Sichuan da xue xue bao Yi xue ban = J Sichuan Univ Med Sci Ed. 2019; 50(1): 88-108. [China]. https://www.ncbi.nlm.nih.gov/pubmed/31037911
  10. Hlapčić I, Belamarić D, Bosnar M, Kifer D, Vukić Dugac A, Rumora L. Combination of systemic inflammatory biomarkers in assessment of chronic obstructive pulmonary disease: Diagnostic performance and identification of networks and clusters. Diagnostics. 2020; 10(12): 1029. https://www.ncbi.nlm.nih.gov/pubmed/33266187. https://www.ncbi.nlm.nih.gov/pmc/articles/7760570. https://doi.org/10.3390/diagnostics10121029
  11. Pryshchepenko VA, Yupatov GY, Okulych VK. Rol fermentnykh system organyzma v razvytyy khronycheskykh zabolevanyy pecheny [The role of the organism enzyme systems in the development of chronic liver diseases]. Dokazatelnaya gastroenterologyya. 2018; 7(2): 35-43. [Russian]
  12. Averyanov AV. Rol neytrofylnoy elastazy v patogeneze khronycheskoy obstruktyvnoy bolezny legkykh [The role of neutrophil elastase in the pathogenesis of chronic obstructive pulmonary disease]. Tsytokyny y vospalenye. 2007; 6(4): 3-8. [Russian]
  13. Beloborodova EV, Beloborodova EY, Akbasheva OE, Serebrov VYu, Chernogoryuk GE, Rachkovskiy MY, et al. Aktivnost elastazo-, kollagenazopodobnykh proteinaz i ikh ingibitorov v plazme krovi pri metabolizme kollagena v usloviyakh khronicheskogo techeniya zabolevaniy pecheni virusnoy i toksycheskoy etiologii [The activity of elastazo-, collagenase-like proteinases and their blood plasma inhibitors in the metabolism of collagen in the conditions of chronic flow of liver disease of viral and toxic etiology]. Sybyrskyy nauchnyy medytsynskyy zhurnal. 2010; 30(2). [Russіan]
  14. Groutas WC, Dou D, Alliston KR. Neutrophil elastase inhibitors. Expert Opin Ther Pat. 2011; 21(3): 339-54. https://www.ncbi.nlm.nih.gov/pubmed/21235378. https://www.ncbi.nlm.nih.gov/pmc/articles/3079352. https://doi.org/10.1517/13543776.2011.551115
  15. DiCamillo SJ, Yang S, Panchenko M V, Toselli PA, Naggar EF, Rich CB, et al. Neutrophil elastase-initiated EGFR/MEK/ERK signaling counteracts stabilizing effect of autocrine TGF-$β$ on tropoelastin mRNA in lung fibroblasts. Am J Physiol Cell Mol Physiol. 2006; 291(2): L232-L243. https://www.ncbi.nlm.nih.gov/pubmed/16473861. https://doi.org/10.1152/ajplung.00530.2005
  16. Pryshchepenko VA, Yupatov GY, Okulych VK. Aktyvnost neytrofylnoy elastazy syvorotky krovy u patsyentov s khronycheskymy zabolevanyyamy pecheny [Neutrophilic elastase activity of blood serum in patients with chronic liver diseases]. Dostizheniya fundamentalnoy, klinicheskoy meditsiny i farmatsii: materialy 73-y nauch ses VGMU. 2018. s. 220-223. [Russian]
  17. Khura J, Khurana TR, Mehra S, Singh P, others. Evaluation of Pro-Inflammatory Markers IL-6 and TNF-a and their Correlation with Non-Alcoholic Fatty Liver Disease. J Adv Res Med. 2019; 6(2): 1-6. https://doi.org/10.24321/2349.7181.201906